Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N, Tenn S, Veruttipong D, Wang J, Hegde J, Lee C, Cao M, Agazaryan N, Steinberg M, Kupelian P, Lee P. Shaverdian N, et al. Among authors: veruttipong d. Br J Radiol. 2016;89(1059):20150963. doi: 10.1259/bjr.20150963. Epub 2016 Jan 14. Br J Radiol. 2016. PMID: 26764282 Free PMC article.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Shaverdian N, et al. Among authors: veruttipong d. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Lancet Oncol. 2017. PMID: 28551359 Free PMC article. Clinical Trial.
Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA, Ilg AM, Veruttipong D, Tan HJ, Burke MA, Niedzwiecki DR, Kupelian PA, King CR, Steinberg ML, Kundavaram CR, Kamrava M, Kaplan AL, Moriarity AK, Hsu W, Margolis DJ, Hu JC, Saigal CS. Laviana AA, et al. Among authors: veruttipong d. Cancer. 2016 Feb 1;122(3):447-55. doi: 10.1002/cncr.29743. Epub 2015 Nov 2. Cancer. 2016. PMID: 26524087 Free article.
Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU. Hegde JV, et al. Among authors: veruttipong d. Urology. 2017 Sep;107:171-177. doi: 10.1016/j.urology.2017.05.028. Epub 2017 May 25. Urology. 2017. PMID: 28552819 Free PMC article.
Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M. Hegde JV, et al. Among authors: veruttipong d. Brachytherapy. 2017 Nov-Dec;16(6):1106-1112. doi: 10.1016/j.brachy.2017.07.008. Epub 2017 Aug 12. Brachytherapy. 2017. PMID: 28807747
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.
Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM. Hegde JV, et al. Among authors: veruttipong d. Cancer. 2018 Feb 1;124(3):521-529. doi: 10.1002/cncr.30954. Epub 2017 Oct 17. Cancer. 2018. PMID: 29044458 Free PMC article. Clinical Trial.
31 results